Physician profile
Christopher Debord
NPI 1790304798
$2,699.72
in general payments reported to CMS, 2019-2025
14 companies · $898 in 2025
The $898 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $608 · 2024: $1,194 · 2025: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,333 · Education: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,332.72 |
| Education | $367.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $649.78 | 2023-2025 | Va-Lcp, Na, Fibulink |
| Stryker Corporation | $560.19 | 2023-2025 | Mako, Pangea, Insignia |
| Medical Device Business Services, INC. | $410.46 | 2023-2025 | Actis, Monocryl |
| Inari Medical, INC. | $184.85 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Pinnacle, INC | $170.49 | 2023-2025 | |
| Sanara Medtech INC. | $153.29 | 2024 | Celleraterx |
| Linvatec Corporation | $147.13 | 2024 | Biobrace 23mm |
| Pacira Pharmaceuticals Incorporated | $120.83 | 2023 | Iovera |
| Heraeus Medical, LLC. | $119.16 | 2024 | |
| Kerecis Limited | $69.03 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Merz Pharmaceuticals, LLC | $42.91 | 2023 | Xeomin |
| Heron Therapeutics, INC. | $24.19 | 2025 | Zynrelef |
| Janssen Biotech, INC. | $23.91 | 2023 | Symtuza |
| Indivior INC. | $23.50 | 2023 | Sublocade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Debord listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.